表紙:鼻結膜炎:パイプライン製品の分析
市場調査レポート
商品コード
363111

鼻結膜炎:パイプライン製品の分析

Rhino-Conjunctivitis - Pipeline Review, H2 2019

出版日: | 発行: Global Markets Direct | ページ情報: 英文 74 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.33円
鼻結膜炎:パイプライン製品の分析
出版日: 2019年12月27日
発行: Global Markets Direct
ページ情報: 英文 74 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、鼻結膜炎治療薬の開発状況関する情報を提供しており、開発段階、薬剤標的、作用機序、投与経路および分子タイプ別の分析、治療薬の開発に従事している企業の概要、最新ニュースやプレスリリースなどの情報をお届けします。

イントロダクション

  • 調査範囲

鼻結膜炎の概要

治療薬の開発

  • パイプライン製品の概要

鼻結膜炎:企業で開発中の治療薬

鼻結膜炎:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

鼻結膜炎:企業で開発中の製品

鼻結膜炎の治療薬開発に従事している企業

  • ALK-Abello A/S
  • Allergy Therapeutics Plc
  • ASIT biotech s.a.
  • Bial - Portela & Ca, S.A.
  • Circassia Pharmaceuticals Plc
  • Faes Farma, S.A.
  • Griffin Discoveries BV
  • HAL Allergy BV
  • Immunomic Therapeutics, Inc.
  • Laboratorios LETI S.L.
  • Oxagen Limited
  • Roxall Medizin GmbH
  • Stallergenes SAS

鼻結膜炎:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

鼻結膜炎:休止中のプロジェクト

鼻結膜炎:開発が中止された製品

鼻結膜炎:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

List of Tables

  • Number of Products under Development for Rhino-Conjunctivitis, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Rhino-Conjunctivitis - Pipeline by ALK-Abello AS, H2 2019
  • Rhino-Conjunctivitis - Pipeline by Allergy Therapeutics Plc, H2 2019
  • Rhino-Conjunctivitis - Pipeline by ASIT Biotech SA, H2 2019
  • Rhino-Conjunctivitis - Pipeline by Faes Farma SA, H2 2019
  • Rhino-Conjunctivitis - Pipeline by HAL Allergy BV, H2 2019
  • Rhino-Conjunctivitis - Pipeline by Iltoo Pharma, H2 2019
  • Rhino-Conjunctivitis - Pipeline by Inmunotek SL, H2 2019
  • Rhino-Conjunctivitis - Pipeline by Laboratorios LETI SL, H2 2019
  • Rhino-Conjunctivitis - Pipeline by Roxall Medizin GmbH, H2 2019
  • Rhino-Conjunctivitis - Dormant Projects, H2 2019
  • Rhino-Conjunctivitis - Dormant Projects, H2 2019 (Contd..1), H2 2019
  • Rhino-Conjunctivitis - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Rhino-Conjunctivitis, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Targets, H2 2019
  • Number of Products by Stage and Targets, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
目次
Product Code: GMDHC11796IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rhino-Conjunctivitis - Pipeline Review, H2 2019, provides an overview of the Rhino-Conjunctivitis (Ophthalmology) pipeline landscape.

Rhinitis is characterized by one or several of the following symptoms: nasal congestion, runny nose, post-nasal drip, sneezing, red eyes (conjunctivitis), and itching of the nose or eyes. It may be allergic or non-allergic. It is important to enact environmental control measures to avoid the allergens that are causing the problem.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rhino-Conjunctivitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Rhino-Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rhino-Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Rhino-Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 6, 6, 1 and 1 respectively.

Rhino-Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rhino-Conjunctivitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Rhino-Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rhino-Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rhino-Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rhino-Conjunctivitis (Ophthalmology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rhino-Conjunctivitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rhino-Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Rhino-Conjunctivitis - Overview
    • Rhino-Conjunctivitis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Rhino-Conjunctivitis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Rhino-Conjunctivitis - Companies Involved in Therapeutics Development
    • ALK-Abello AS
    • Allergy Therapeutics Plc
    • ASIT Biotech SA
    • Faes Farma SA
    • HAL Allergy BV
    • Iltoo Pharma
    • Inmunotek SL
    • Laboratorios LETI SL
    • Roxall Medizin GmbH
  • Rhino-Conjunctivitis - Drug Profiles
  • Rhino-Conjunctivitis - Dormant Projects
  • Rhino-Conjunctivitis - Discontinued Products
  • Rhino-Conjunctivitis - Product Development Milestones
  • Appendix